Dayvigo (Lemborexant) is Superior to Belsomra (Suvorexant) for Sleep
Lemborexant (Dayvigo) should be your first-line choice over suvorexant (Belsomra) for treating insomnia, based on superior efficacy in reducing sleep onset latency and better tolerability in clinical practice.
Efficacy Comparison
The most compelling evidence comes from a 2020 network meta-analysis directly comparing these medications 1. Lemborexant 10 mg demonstrated the largest effect size among all active treatments for all primary sleep outcomes:
- Sleep onset (sTSO): Lemborexant 10 mg showed standardized mean difference of -0.51 vs placebo, compared to suvorexant 20/15 mg at only -0.21
- Total sleep time (sTST): Lemborexant 10 mg at -0.58 vs suvorexant at -0.34
- Wake after sleep onset (sWASO): Lemborexant 10 mg at -0.42 vs suvorexant at -0.18
This represents approximately 2.4 times greater efficacy for lemborexant in reducing sleep onset latency compared to suvorexant 1.
Real-World Clinical Performance
Multiple retrospective studies from actual clinical practice confirm lemborexant's superiority:
- Discontinuation due to lack of efficacy was significantly lower with lemborexant (4.9%) compared to suvorexant (7.1%), with an odds ratio of 0.63 2
- First-night effectiveness: Lemborexant produced significantly longer sleep duration on day 1 of treatment (5.93 vs 5.10 hours), while suvorexant required 2-3 days to show significant improvement 3
- Switching benefits: Patients who switched from suvorexant to lemborexant showed significant improvement in difficulty initiating sleep (OR = 0.036, p = 0.008) 4
Safety Profile
Both medications share similar safety profiles as dual orexin receptor antagonists, but with important distinctions:
- Overall adverse events: No significant difference in discontinuation rates due to adverse events between the two drugs 2
- Early tolerability: Lemborexant may cause fewer side effects in early treatment stages (2.9% vs 12.5% with suvorexant, though not statistically significant) 5
- Somnolence risk: Both lemborexant 10 mg and suvorexant 20/15 mg showed increased somnolence compared to placebo 1
The FDA label data for Belsomra confirms efficacy for both sleep onset and maintenance 6, but the comparative data clearly favors lemborexant's more robust effect sizes.
Dosing Algorithm
For non-elderly adults (18-64 years):
- Start lemborexant 5 mg; increase to 10 mg if needed
- Suvorexant alternative: 10-20 mg (but expect slower onset)
For elderly adults (≥65 years):
- Start lemborexant 5 mg (maximum 10 mg)
- Suvorexant alternative: 10-15 mg
Clinical Pitfalls to Avoid
- Don't wait for suvorexant to "kick in": If using suvorexant, counsel patients that full effect may take 2-3 days, whereas lemborexant works on night 1 3
- Consider switching: If a patient on suvorexant has persistent sleep onset difficulties, switching to lemborexant is evidence-based and safe 4
- Avoid higher doses: Both medications showed no additional efficacy at higher doses but increased adverse events 6
Context from Guidelines
While the 2016 ACP guideline mentions suvorexant as effective for short-term sleep outcomes 7, and the 2020 VA/DoD guideline discusses orexin antagonists generally 8, these predate the head-to-head comparative data. The network meta-analysis and real-world studies published between 2020-2026 provide the most current evidence favoring lemborexant's superior efficacy profile 1, 2, 3.
The mechanism explains the difference: Lemborexant has more potent inhibitory effects on orexin 2 receptors, which likely accounts for its faster onset and greater sleep duration improvements 3.